Lupin gains on its arm receiving tentative approval for generic Glumetza ER tablets

31 Jan 2012 Evaluate

Lupin is currently trading at Rs. 475.00, up by 4.40 points or 0.93% from its previous closing of Rs. 470.60 on the BSE.

The scrip opened at Rs. 475.00 and has touched a high and low of Rs. 478.95 and Rs. 473.00 respectively. So far 4,440 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 492.00 on 21-Sep-2011 and a 52 week low of Rs. 363.00 on 25-Feb-2011.

Last one week high and low of the scrip stood at Rs. 478.95 and Rs. 446.75 respectively. The current market cap of the company is Rs. 21,208.00 crore.

The promoters holding in the company stood at 46.93% while Institutions and Non-Institutions held 43.44% and 9.63% respectively.

Lupin’s US subsidiary - Lupin Pharmaceuticals, Inc. (LPI) has received tentative approval for its Metformin Hydrochloride Extended Release Tablets (HCl ER) 500 mg and 1000 mg from the United States Food and Drugs Administration (USFDA).

Lupin’s Metformin HCl ER Tablets, 500 mg and 1000 mg strengths are the AB-rated generic equivalent of Santarus, Inc.’s Glumetza HCl ER Tablets, 500 mg and 1000 mg strengths. Metformin HCl ER tablets is a biguanide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

As per IMS Health data, Glumetza HCl ER tablets, 500 mg and 1000 mg had annual US sales of approximately $58 million, for the twelve months ending Sep, 2011. The company believes that it is the first applicant to file an ANDA for Glumetza HCL ER Tablets, 500 mg & 1000 mg strengths and as such will be entitled to 180 days of marketing exclusivity.

Lupin has a vibrant presence in the Indian pharmaceuticals market and has over the past several years made major strides in expanding its therapy portfolio. The company has a robust promotion and distribution setup along with a strong presence in various therapeutic areas, including the fast growing diabetes market.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×